Pyrrolobenzodiazepine Antibody Drug Conjugates via Disulfide Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in optimizing antibody selection, linker design, and stability, which affects their efficacy in targeting and internalizing cytotoxic drugs to tumor cells effectively.
Innovation Solution
The development of antibody-drug conjugates using monoalkylator pyrrolobenzodiazepine drug moieties covalently attached to antibodies via a disulfide linker, specifically designed for therapeutic or diagnostic applications, targeting various tumor-associated antigens and cell-surface receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADCs use traditional linker designs and cytotoxic drugs, then they can deliver therapeutic agents to tumor cells, but their efficacy is limited by suboptimal antibody selection, linker stability, and drug internalization
Solution Approach 1:
The patent changes the chemical parameters of the linker-drug conjugate by using pyrrolobenzodiazepine intermediates with specific chemical properties (electrophilic centers, reactive functional groups) that improve upon conventional ADC parameters. The intermediate structure enables optimized conjugation chemistry with antibodies, improving therapeutic efficacy through parameter optimization rather than fundamental design changes
Solution Approach 2:
The pyrrolobenzodiazepine intermediate serves as a mediator between the antibody and the final cytotoxic drug. This intermediate compound facilitates the conjugation process and enables controlled drug release through its specific chemical reactivity patterns, acting as a bridge that resolves the complexity of direct antibody-drug coupling
2Object-affected harmful factors
If ADCs are designed to target tumor cells with high specificity, then anti-tumor activity is enhanced, but the complexity of optimizing antibody-drug conjugation increases
Solution Approach 1:
The patent modifies the chemical parameters of the conjugation process by introducing pyrrolobenzodiazepine intermediates with specific reactivity characteristics. These intermediates have controlled electrophilic centers that react with antibody thiol groups under optimized conditions, making the conjugation process more manageable while maintaining high target specificity and anti-tumor activity
3Productivity
If traditional cytotoxic drugs are used in ADCs, then they can be delivered to tumor cells, but drug internalization and release efficiency is insufficient
Solution Approach 1:
The pyrrolobenzodiazepine intermediate acts as a mediator that improves drug delivery efficiency. Its chemical structure includes functional groups that facilitate cellular uptake and controlled intracellular release of the cytotoxic agent, enhancing productivity in drug delivery without compromising the potency of the cytotoxic drug payload
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the therapeutic efficacy of ADCs by specifically targeting tumor cells, improving drug internalization and release, thereby increasing anti-tumor activity and diagnostic accuracy.
Implementation Method 1
monoalkylator pyrrolobenzodiazepine drug moieties covalently attached to antibodies via a disulfide linker
Implementation Method 2
Certain pyrrolobenzodiazepine (PBD) compounds have the ability to recognize and bond to specific sequences of DNA... the electrophilic center responsible for alkylating DNA
Implementation Method 3
PBD to form an adduct in the minor groove, enables them to interfere with DNA processing
Implementation Method 4
targeting potent cytotoxic drugs to antigen-expressing tumor cells... targeting various tumor-associated antigens and cell-surface receptors
Implementation Method 5
internalization, and release of drug, thereby enhancing their anti-tumor activity... improving drug internalization and release
Data Source
AI summary
The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.